E. Lahat et al., Bone mineral density and turnover in children with attention-deficit hyperactivity disorder receiving methylphenidate, J CHILD NEU, 15(7), 2000, pp. 436-439
Attention-deficit hyperactivity disorder (ADHD) is the most common behavior
disorder among children; methylphenidate is a drug frequently prescribed f
or the control of its symptoms. One of the potential side effects of methyl
phenidate that concerns parents is its impact on the growth of children, si
nce the mechanism by which methylphenidate might influence growth is not kn
own. As Linear growth is associated with an increase in bone mineral densit
y and turnover, this study was undertaken to evaluate bone mineral density
by dual photon absorptiometry and bone turnover by measuring serum bone-spe
cific alkaline phosphatase and the urinary deoxypyridinoline excretion rate
in children treated with methylphenidate for 1 to 2 years as compared to a
control group. There were no significant differences in bone mineral densi
ty at either the lumbar spine or femoral neck in the study group (0.662 +/-
0.04 and 0.735 +/- 0.97 g/cm(2), respectively) as compared to the controls
(0.675 +/- 0.05 g/cm(2) and 0.734 +/- 0.07 g/cm(2), respectively). Further
more, there were no significant differences in serum bone-specific alkaline
phosphatase in the study group (58 +/- 22 U/L) as compared to the control
children (71 +/- 34 U/L) or in urinary deoxypyridinoline in the study group
(34 +/- 38 nM/mM), as compared to the control group (27 +/- 12 nM/mM). In
conclusion, our data do not support a significant effect of methylphenidate
on bone mineral density turnover in children when used for I to 2 years.